Serina Therapeutics, Inc. (SER) — SEC Filings
Serina Therapeutics, Inc. (SER) — 50 SEC filings. Latest: 8-K (Apr 21, 2026). Includes 34 8-K, 5 10-Q, 2 10-K.
View Serina Therapeutics, Inc. on SEC EDGAR
Overview
Serina Therapeutics, Inc. (SER) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-8 filed on Mar 25, 2026: Serina Therapeutics, Inc. filed an S-8 on March 25, 2026, to register securities for its employee benefit plans. This filing, with File No. 333-294614, allows the company to issue shares to employees, which is a common way to attract and retain talent. For investors, this matters because it indicate
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 2 bearish, 46 neutral, 2 mixed. The dominant filing sentiment for Serina Therapeutics, Inc. is neutral.
Filing Type Overview
Serina Therapeutics, Inc. (SER) has filed 1 4, 34 8-K, 1 S-8, 2 10-K, 5 10-Q, 2 DEF 14A, 2 SC 13D/A, 1 SC 13G/A, 2 S-1/A with the SEC between May 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of SER's 45 recent filings, 3 were flagged as high-risk, 22 as medium-risk, and 20 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | N/A |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | N/A |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Steve Ledger
- Karen J. Wilson
- Balkrishan "Simba" Gill, Ph.D.
- Stephen Brannan, M.D.
- Gregory Curhan
- Dr. David E. Bearss
- Dr. Robert E. T. Smith
- Dr. David L. Bearss
- David Gill
- Dr. David E. Smith
- Ms. Sarah E. Johnson
- Dr. David E. Johnson
- Ms. Jennifer L. Johnson
Industry Context
Serina Therapeutics operates in the highly competitive clinical-stage biotechnology sector, focusing on neurological diseases. This field is characterized by significant R&D investment, long development timelines, and high failure rates. Companies often rely on proprietary drug delivery platforms, like Serina's POZ technology, to differentiate their candidates. The industry is also seeing increased interest in novel modalities such as RNA-based therapeutics and ADCs, alongside traditional small molecules.
Top Tags
financials (9) · 8-K (6) · filing (6) · corporate-governance (5) · financial-reporting (5) · Biotechnology (4) · disclosure (4) · 10-Q (4) · sec-filing (4) · SEC Filing (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Aggregate market value of non-affiliate common stock | $21.8M | as of June 30, 2025, indicating a small market capitalization |
| Shares of common stock outstanding | 12,314,159 | as of March 18, 2026 |
| Fiscal year end | 2025-12-31 | for which the 10-K was filed |
| FDA IND clearance for SER-252 | 2026-01 | key regulatory milestone for lead candidate |
| First patient dosed in Phase 1b for SER-252 | 2026-02 | initiation of clinical trial for lead candidate |
| Subjects in SER-214 Phase Ia study | 19 | completed proof-of-principle study |
| Net Loss | $15.8M | for the nine months ended September 30, 2025, significantly higher than $8.4M in prior year |
| Net Cash Used in Operating Activities | $11.9M | for the nine months ended September 30, 2025, indicating high cash burn |
| Cash and Cash Equivalents | $8.6M | as of September 30, 2025, deemed insufficient for next 12 months |
| Research and Development Expenses | $9.75M | for the nine months ended September 30, 2025, up from $5.11M in 2024 |
| Proceeds from Series A Convertible Preferred Stock | $4.94M | net proceeds from financing activities |
| Proceeds from At-The-Market Sales Agreement | $2.15M | net proceeds from financing activities |
| Common Shares Outstanding | 10,664,064 | as of November 10, 2025, indicating potential for dilution |
| Total Revenues | $130K | for the nine months ended September 30, 2025, primarily from grants |
| Annual Meeting Date | 2025-11-07 | Date of the virtual Annual Meeting of Stockholders |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Serina Therapeutics, Inc. (SER)?
Serina Therapeutics, Inc. has 50 recent SEC filings from May 2024 to Apr 2026, including 34 8-K, 5 10-Q, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SER filings?
Across 50 filings, the sentiment breakdown is: 2 bearish, 46 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Serina Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Serina Therapeutics, Inc. (SER) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Serina Therapeutics, Inc.?
Key financial highlights from Serina Therapeutics, Inc.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SER?
The investment thesis for SER includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Serina Therapeutics, Inc.?
Key executives identified across Serina Therapeutics, Inc.'s filings include Steve Ledger, Karen J. Wilson, Balkrishan "Simba" Gill, Ph.D., Stephen Brannan, M.D., Gregory Curhan and 8 others.
What are the main risk factors for Serina Therapeutics, Inc. stock?
Of SER's 45 assessed filings, 3 were flagged high-risk, 22 medium-risk, and 20 low-risk.
What are recent predictions and forward guidance from Serina Therapeutics, Inc.?
Forward guidance and predictions for Serina Therapeutics, Inc. are extracted from SEC filings as they are enriched.